US Patent

US10385008 — Polymorphic forms of RAD1901-2HCL

Composition of Matter · Assigned to Radius Pharmaceuticals Inc · Expires 2038-01-05 · 12y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects various polymorphic forms of RAD1901-2HCl, including crystalline and amorphous forms, for use in cancer treatment.

USPTO Abstract

Various polymorphic forms of RAD1901-2HCl, including three crystalline and amorphous forms, are prepared and characterized. Uses of the various polymorphic forms of RAD1901-2HCl for cancer treatment are also disclosed.

Drugs covered by this patent

elacestrant-hydrochloride (ELACESTRANT HYDROCHLORIDE)

Patent Metadata

Patent number: US10385008
Jurisdiction: US
Classification: Composition of Matter
Expires: 2038-01-05
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Radius Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.